A Study of CS3002 in Subjects With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2021-02-19
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety,
tolerability, pharmacokinetics and anti-tumor activity of CS3002 in subjects with advanced
solid tumors.